Tenaya’s Chief Executive Officer, will participate in TD Cowen’s 45 th Annual Health Care Conference and the Leerink Partners Global Healthcare Conference 2025. Details are as follows ...

Dosing Initiated in Cohort 2 of the MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 for Treatment of MYBPC3-Associated Hypertrophic ...

Chief Executive Officer of Tenaya. “The recent financing with support from existing and new shareholders allows us to maintain our focus on driving our gene therapy programs for cardiomyopathies ...

As of December 31 cash, cash equivalents and investments in marketable securities were $61.4M compared to $104.6M as of December 31. With the ...

Detailed price information for Tenaya Therapeutics Inc (TNYA-Q) from The Globe and Mail including charting and trades.

Tenaya Therapeutics is a clinical-stage biotechnology ... Tova Gardin, MD, MPP, Chief Translational Officer at Biohaven, commented, “BHV-1300 has demonstrated remarkable efficacy in deep ...

Tenaya Therapeutics, Inc. announced that it will present new data on its MYBPC3-associated hypertrophic cardiomyopathy (HCM) program at the American College of Cardiology's Annual Scientific ...